


Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

Graphical abstract



Authors

Jonel Trebicka, Wenyi Gu, Luis Ibáñez-Samaniego, ..., Juan Carlos Garcia-Pagán, Christian Jansen, Rafael Bañares

Correspondence

jonel.trebicka@kgu.de (J. Trebicka).

Lay summary

Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt.

Highlights

- Variceal bleeding is frequently associated with ACLF in cirrhosis.
- ACLF is independently associated with rebleeding and mortality.
- Patients with variceal bleeding and ACLF can benefit from a pre-emptive (early) TIPS.



Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

Jonel Trebicka^{1,2,3,4,*}, Wenyi Gu^{1,3,5}, Luis Ibáñez-Samaniego⁶, Virginia Hernández-Gea^{7,8}, Carla Pitarch³, Elisabet Garcia³, Bogdan Procopet⁹, Álvaro Giráldez¹⁰, Lucio Amitrano¹¹, Candid Villanueva^{8,12}, Dominique Thabut¹³, Gilberto Silva-Junior⁷, Javier Martinez¹⁴, Joan Genescà^{8,15}, Christophe Bureau¹⁶, Elba Llop^{8,17}, Wim Laleman¹⁸, Jose Maria Palazon¹⁹, Jose Castellote²⁰, Susanag Rodrigues²¹, Liselotte Gluud²², Carlos Noronha Ferreira²³, Rafael Barcelo²⁴, Nuria Cañete²⁵, Manuel Rodríguez²⁶, Arnulf Ferlitsch²⁷, Jose Luis Mundi²⁸, Henning Gronbaek²⁹, Manuel Hernández-Guerra³⁰, Romano Sassatelli³¹, Alessandra Dell'Era³², Marco Senzolo³³, Juan G. Abraldes³⁴, Manuel Romero-Gómez^{8,35}, Alexander Zipprich³⁶, Meritxell Casas³⁷, Helena Masnou³⁸, Massimo Primignani³⁹, Emmanuel Weiss³, Maria-Vega Catalina⁶, Hans-Peter Erasmus¹, Frank Erhard Uschner¹, Martin Schulz¹, Maximilian J. Brod⁴⁰, Michael Praktiknjo⁴⁰, Johannes Chang⁴⁰, Aleksander Krag², Frederik Nevens¹⁸, Jose Luis Calleja^{8,17}, Marie Angèle Robic¹⁶, Irene Conejo^{8,15}, Agustin Albillos^{8,14}, Marika Rudler¹³, Edilmar Alvarado^{8,12}, Maria Anna Guardascione¹¹, Marcel Tantau⁹, Jaime Bosch^{7,8,41}, Ferran Torres^{24,42}, Marco Pavesi³, Juan Carlos Garcia-Pagán^{7,8}, Christian Jansen⁴⁰, Rafael Bañares^{8,43}, for the International Variceal Bleeding Observational Study Group and Baveno Cooperation

¹Department of Internal Medicine I, University of Frankfurt, Frankfurt, Germany; ²Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark; ³European Foundation for the Study of Chronic Liver Failure - EF CLIF, Barcelona, Spain; ⁴Institute for Bioengineering of Catalonia, Barcelona, Spain; ⁵Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; ⁶Servicio de Medicina de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, IISGM, CIBERehd, Madrid, Spain; ⁷Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, IMDIM, University of Barcelona, Barcelona, Spain, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver); ⁸Centro de Investigación Biomédica Red de enfermedades hepáticas y digestivas (CIBERehd), Madrid, Spain; ⁹Regional Institute of Gastroenterology and Hepatology "Octavian Fodor", Hepatology Department and "Iuliu Hatieganu" University of Medicine and Pharmacy, 3rd Medical Clinic, Cluj-Napoca, Romania; ¹⁰Clinical Management Unit of Digestive Diseases, University Hospital Virgen del Rocío, Seville, Spain; ¹¹Gastroenterology Unit, Ospedale A Cardarelli, Naples, Italy; ¹²Servei de Patologia Digestiva, Hospital de la Santa Creu i Sant Pau and CIBERehd, Barcelona, Spain; ¹³Groupement Hospitalier Pitié-Salpêtrière-Charles Foix; Paris Sorbonne Université, Paris, France; ¹⁴Department of Gastroenterology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), University of Alcalá, CIBERehd, Madrid, Spain; ¹⁵Liver Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona and CIBERehd, Barcelona, Spain; ¹⁶Department of Hepatology, Rangueil Hospital, CHU Toulouse, University Paul Sabatier of Toulouse, France; ¹⁷Liver Unit, Hospital U, Puerta de Hierro, Universidad Autónoma de Madrid, CIBERehd, Madrid, Spain; ¹⁸Department of Gastroenterology and Hepatology, University Hospital KU Leuven, Leuven, Belgium; ¹⁹Hospital General Universitario de Alicante, Alicante, Spain; ²⁰Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain; ²¹Gastroenterology and Hepatology Department, Centro Hospitalar São João, Porto, Portugal; ²²Gastrounit, Medical Division, University Hospital of Hvidovre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ²³Serviço de Gastreenterologia e Hepatologia, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Lisbon, Portugal; ²⁴Medical Statistics Core Facility, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain; ²⁵Liver Section, Gastroenterology Department, Hospital del Mar, Universitat Autònoma de Barcelona, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; ²⁶Department of Gastroenterology, Hospital Central de Asturias, Oviedo, Spain; ²⁷Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria; ²⁸Department of Gastroenterology, University Hospital San Cecilio, Granada, Spain; ²⁹Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; ³⁰Gastroenterology Department, University Hospital of the Canary Islands, La Laguna, Tenerife, Spain; ³¹Unit of Gastroenterology and Digestive Endoscopy, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy; ³²Gastroenterology Unit, ASST Fatebenefratelli Sacco, Department of Clinical and Biomedical Sciences, University of the Studies of Milan, Milan, Italy; ³³Multivisceral Transplant Unit, Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padua, Padua, Italy; ³⁴Cirrhosis Care Clinic, Division of Gastroenterology (Liver Unit), CEGIIR, University of Alberta, Edmonton, Canada;

Keywords: Acute variceal bleeding; Acute-on-chronic liver failure; Cirrhosis; Rebleeding.

Received 24 January 2020; received in revised form 7 April 2020; accepted 9 April 2020; available online 24 April 2020

* Corresponding author. Address: Department of Internal Medicine I, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. Tel.: +49 69 6301 4256.

E-mail address: jonel.trebicka@kgu.de (J. Trebicka).

† Shared first and last authorships.

<https://doi.org/10.1016/j.jhep.2020.04.024>



³⁵Unidad de Hepatología, Hospital Universitario de Valme, CIBERehd, Sevilla, Spain; ³⁶First Department of Internal Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; ³⁷Hepatology Unit, Digestive Disease Department Hospital de Sabadell, Universitat Autònoma de Barcelona, Sabadell, Spain; ³⁸Hospital Universitari Germans Trias i Pujol, Universitat Autònoma Barcelona, Badalona, Spain; ³⁹Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC "A.M. and A. Migliaivacca" Center for Liver Disease, Milan, Italy; ⁴⁰Department of Internal Medicine I, University of Bonn, Bonn, Germany; ⁴¹Swiss Liver Centre, Inselspital, Bern University, Bern, Switzerland; ⁴²Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁴³Gregorio Marañón University General Hospital, Gregorio Marañón Sanitary Research Institute, Faculty of Medicine, Complutense University of Madrid, Spain

Background & Aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date.

Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality.

Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; $p < 0.001$) and mortality (47% vs. 10%; $p < 0.001$) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not.

Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality in patients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB.

Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt.

© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Acute variceal bleeding (AVB), which accounts for 70% of all upper gastrointestinal bleeding episodes in cirrhosis,¹ has been identified as a common cause of death in patients with cirrhosis, with a 6-week mortality around 20%.² At present, progress has been made in the treatment of AVB, including endoscopic treatment, drug therapy, and transjugular intrahepatic portosystemic shunt (TIPS).^{3,4} However, 10–20% of patients with AVB experience treatment failure after initial endoscopic and medical treatment, which is associated with a high short-term risk of further liver decompensation and death.⁵

Several factors have been proposed to identify patients with AVB who are at high risk of poor outcomes and treatment failure, such as the model for end-stage liver disease (MELD) score, renal failure, bacterial infection and active bleeding at endoscopy.^{2,6,7} The Baveno VI Consensus recommends the use of pre-emptive TIPS (pTIPS) in cirrhotic patients with Child-Pugh B cirrhosis and active bleeding at endoscopy despite being on vasoactive drugs, and in patients with Child-Pugh C (<14 points).⁸ Several studies have shown that pTIPS placed within 24–72 hours after admission, leads to a significant improvement in relevant clinical outcomes.^{5,9–12} pTIPS prevents rebleeding and ascites without increasing the complication of hepatic encephalopathy (HE),¹³ and is thus a milestone in the treatment of cirrhotic patients with AVB. The benefits of pTIPS probably rely on the prevention of further deterioration after failure of initial treatment, avoiding subsequent increase in rebleeding, organ failure and death.¹⁴ This condition frequently meets the criteria of acute-on-chronic liver failure (ACLF), which comprises a rapidly deteriorating syndrome with extremely high short-term mortality.¹⁵ With a prevalence of over 22%, ACLF is common in cirrhotic patients with acute decompensation.^{15,16} AVB is a well-known trigger for the development of ACLF.^{17,18} However, the role of ACLF in the outcome of patients with AVB has not yet been investigated.

This multicenter, international, observational study addresses 3 clinically relevant issues: i) the prevalence of ACLF at admission in patients with AVB; ii) the influence of ACLF at admission on AVB outcomes (rebleeding and mortality); iii) the impact of pTIPS on mortality of patients with ACLF and AVB.

Patients and methods

Study design and patients

This study has been conducted using the database of a multicenter, international, prospective observational study by the Baveno Cooperation to evaluate AVB in cirrhotic patients in 34 centers between October 2011 and May 2015. The study protocol (see [supplementary information and CTAT table](#)) and details were published previously.¹³ All patients were managed according to the guidelines of the Baveno V consensus and the AASLD guidelines.¹⁹ Patients at high risk of variceal rebleeding, *i.e.* with either Child-Pugh grade C cirrhosis, or grade B cirrhosis with active bleeding at endoscopy despite the use of vasoactive agents, were considered for pTIPS based on individual center policy.⁵

Patients were regularly followed-up for 1 year, until death, liver transplantation, or the end date of follow-up, whichever came first. Medical history, clinical, biochemistry and endoscopic findings, treatments and outcomes were recorded during hospitalization. The primary outcome of this study was all-cause

Table 1. Baseline characteristics of all patients and patients with or without ACLF.

Baseline characteristics	All patients (n = 2138)	ACLF (n = 380)	Non-ACLF (n = 1758)	p value
Male, n (%)	1,570 (73.4)	286 (75.3)	1,284 (73.1)	0.382
Age	58.0 (50.0–68.0)	57.0 (50.0–67.8)	59.0 (50.0–68.0)	0.356
Etiology of cirrhosis, n (%)	1,006/508/282/342	216/71/45/48	790/437/237/294	<0.001
Alcohol/virus/alcohol & virus/others	(47.1/23.7/13.2/15.9)	(56.8/18.7/11.9/12.6)	(45.0/24.8/13.5/16.8)	
Hepatocellular carcinoma, n (%)	129 (6.0)	24 (6.3)	105 (6.0)	0.799
Portal vein thrombosis, n (%)	33 (15.6)	273 (15.8)	60 (16.0)	0.938
Previous bleeding, n (%)	671 (31.4)	93 (24.5)	578 (32.9)	0.001
Previous episode of decompensation, n (%)				
Ascites	1013 (47.4)	237 (62.4)	776 (44.1)	<0.001
Hepatic encephalopathy	323 (15.1)	111 (29.2)	212 (12.1)	<0.001
Spontaneous bacterial peritonitis/bacteremia	123 (5.8)	52 (13.7)	71 (4.0)	<0.001
Hepatorenal syndrome	40 (1.9)	22 (5.8)	18 (1.0)	<0.001
Decompensation at admission				
Ascites	866 (40.5)	162 (42.6)	704 (40.0)	0.357
Hepatic encephalopathy	618 (28.9)	220 (57.9)	398 (22.6)	<0.001
Bacterial infection	368 (17.2)	132 (34.7)	236 (13.4)	<0.001
Laboratory tests				
Hemoglobin (g/L)	85.0 (66.0–101.0)	78.0 (65.0–93.0)	87.0 (67.0–104.0)	<0.001
Leucocytes (10 ⁹ /L)	7.7 (5.5–11.1)	9.1 (6.0–14.6)	7.5 (5.3–10.5)	<0.001
Platelet count (10 ⁹ /L)	97.0 (67.0–138.8)	90.0 (64.0–136.0)	98.0 (68.0–139.0)	0.013
Creatinine (mg/dl)	0.9 (0.7–1.2)	1.7 (1.0–2.5)	0.8 (0.7–1.0)	<0.001
Urea nitrogen (mg/dl)	49.0 (30.0–76.0)	82.0 (43.0–132.0)	46.0 (28.0–68.0)	<0.001
Na (mEq/L)	137.0 (134.0–140.0)	136.0 (131.0–140.0)	138.0 (134.0–140.0)	<0.001
Bilirubin (mg/dl)	1.7 (1.0–3.1)	2.9 (1.2–7.3)	1.6 (0.9–2.7)	<0.001
Albumin (g/L)	27.1 (23.2–31.0)	26.0 (21.1–30.0)	28.0 (24.0–32.0)	<0.001
AST (U/L)	53.0 (33.0–95.0)	66.0 (36.0–128.8)	50.0 (33.0–90.0)	<0.001
ALT (U/L)	33.0 (21.0–52.0)	36.0 (22.0–63.5)	32.0 (21.0–50.0)	0.006
INR	1.4 (1.3–1.7)	1.7 (1.4–2.4)	1.4 (1.2–1.6)	<0.001
Glucose (mg/dl)	139.0 (112.0–187.3)	140.0 (110.8–180.5)	139.0 (113.0–189.0)	0.257
Organ failures, n (%)				<0.001
Circulatory failure	233 (10.9)	202 (53.2)	31 (1.8)	
Respiratory failure	232 (10.9)	169 (44.5)	63 (3.6)	
Cerebral failure	219 (10.2)	117 (30.8)	102 (5.8)	
Renal failure	163 (7.6)	163 (42.9)	0 (0.0)	
Coagulation failure	112 (5.2)	89 (23.4)	23 (1.3)	
Liver failure	82 (3.8)	66 (17.4)	16 (0.9)	
Length of ICU stay (days) (686/227/459)	5 (2–10)	7 (3–12)	4 (2–8)	<0.001
Scores				
MELD	11.7 (7.6–16.7)	21.4 (17.0–27.4)	10.3 (6.8–14.1)	<0.001
Child-Pugh	8.0 (7.0–10.0)	10.0 (8.0–12.0)	8.0 (7.0–9.0)	<0.001
Child-Pugh class (A/B/C), n (%)	468/1,102/568	45/136/199	423/966/369	<0.001
	(21.9/51.5/26.6)	(11.8/35.8/52.4)	(24.1/54.9/21.0)	

ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICU, intensive care unit; INR, international normalized ratio; MELD, model for end-stage liver disease.

Mann-Whitney *U* test.

mortality or liver transplantation at day 42 and 1 year. The secondary outcome was rebleeding.

In this secondary ancillary study, we analyzed the influence of ACLF at admission in variceal bleeding evolution and the role of pTIPS on the outcomes of patients with ACLF.

For this purpose, ACLF at admission was retrospectively defined and graded according to the EASL-CLIF consortium definition ([supplementary methods](#)).¹⁵ Briefly, liver, kidney and coagulation failure were assessed by bilirubin, creatinine and international normalized ratio (INR) levels that were specifically included in the electronic case report form (CRF). Brain failure was evaluated by HE grades (West Haven). Circulatory failure was considered when vasopressor therapy was needed to maintain blood pressure. A total of 233 patients treated with vasoactive drugs to maintain blood pressure were defined as having circulatory failure. Finally, respiratory failure (n = 232) was diagnosed when mechanical ventilation was required for

reasons other than airway protection and in the absence of HE grade III or IV. Renal replacement therapy was not recorded in any patients, at least at enrollment, but renal dysfunction and failure were based on creatinine values, as defined by the EASL-CLIF ACLF definition. A total of 686 patients were admitted to the intensive care unit (ICU) and the length of ICU stay was recorded, with a median of 5 days.

For the specific analysis of the impact of the relationship between pTIPS in ACLF, patients were excluded if they were older than 75 years, had developed hepatocellular carcinoma outside the Milan criteria, had active sepsis, creatinine levels ≥ 3 mg/dl, heart failure or complete portal vein thrombosis. Only patients who fulfilled the prespecified criteria for pTIPS were included in the analysis on pTIPS ([Fig. S1](#)).

The ethics committees of all participating hospitals approved the study protocol and all participants included in the study provided written informed consent.




Fig. 1. ACLF and risk factors for rebleeding in patients with variceal bleeding. (A) Cumulative incidence function curve of 42-day cumulative rebleeding rate in patients with and without ACLF. Levels of significance: $p < 0.0001$ (Gray's test). (B) Cumulative incidence function curve of 1-year cumulative rebleeding rate in patients with and without ACLF. Levels of significance: $p = 0.024$ (Gray's test). (C) Independent risk factors of 42-day rebleeding in all patients with acute variceal bleeding. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). (D) Independent risk factors of 1-year rebleeding in all patients with acute variceal bleeding. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). ACLF, acute-on-chronic liver failure.

Data management and statistical analysis

Multiple excellence control procedures were used to optimize data quality. This included the use of a unified REDCap electronic data capture system to record and manage data. Additionally, a steering committee was formed to monitor data consistency and correctness.

We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline for reporting observational studies. Continuous variables were described as median and interquartile range, and categorical variables as frequency and percentage. Non-parametric Mann-Whitney U test or Fisher's exact test were used to compare groups of patients where appropriate. Cumulative incidence function curve with Gray's test were used for survival analysis. Univariate and multivariate competitive risk Cox regression models were used to identify independent predictors of 42-day and 1-year rebleeding (liver transplantation or death as competing risks) or mortality (with liver transplantation as competing risks). Potential risk factors that were significant ($p < 0.05$) in the univariate competitive risk Cox regression analysis were included in a multivariate analysis to analyze the subdistribution hazard ratio

(sHR). To confirm the robustness of our results, we performed a sensitivity analysis comparing patients with ACLF receiving pTIPS with those not receiving pTIPS by propensity score matching (1:2).

A 2-tailed p value of < 0.05 was considered statistically significant. All statistical analyses were performed using the SAS software (version 9.4; SAS Institute Inc., Cary, NC) or SPSS (version 19.0; IBM, Chicago, IL).

Results

Baseline characteristics and the prevalence of ACLF at admission in patients with AVB

We included a total of 2,138 patients (Fig. S1). Their baseline characteristics are shown in Table 1. Patients were predominantly male (73.4%), with a median age of 58 years. Alcohol was the most common etiology of liver disease. Of all the patients included, 380 (17.8%) had ACLF at baseline (147 [38.7%], 149 [39.2%] and 84 [22.1%] had ACLF grade 1, 2 and 3, respectively). Age and gender were similar between patients with and without ACLF, but more patients with ACLF had an alcoholic etiology. As expected, patients with ACLF more frequently presented with

Table 2. Competing risk model of 42-day and 1-year rebleeding and mortality in all patients.

	42-day				1-year			
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis	
	HR (95% CI)	p value	sHR (95% CI)	p value	HR (95% CI)	p value	sHR (95% CI)	p value
Risk factor for rebleeding								
Age	0.998 (0.988–1.007)	0.602	0.999 (0.989–1.009)	0.818	0.994 (0.987–1.002)	0.126	0.995 (0.987–1.003)	0.195
Female	0.862 (0.645–1.151)	0.314	0.881 (0.649–1.195)	0.415	0.801 (0.633–1.014)	0.065	0.813 (0.639–1.036)	0.094
ACLF	1.946 (1.482–2.555)	<0.001	1.798 (1.336–2.418)	<0.001	1.313 (1.030–1.674)	0.028	1.535 (1.183–1.992)	0.001
Portal vein thrombosis	1.509 (1.119–2.036)	0.007	1.420 (1.036–1.945)	0.029	1.423 (1.113–1.819)	0.005	1.506 (1.173–1.932)	0.001
Hemoglobin	0.996 (0.992–0.999)	0.010	0.996 (0.992–0.999)	0.019	0.997 (0.994–0.999)	0.017	0.996 (0.993–0.999)	0.006
Infection	1.873 (1.456–2.410)	0.004	1.519 (1.113–2.072)	0.009	1.295 (1.049–1.599)	0.016	1.184 (0.946–1.481)	0.140
Leukocyte	1.014 (1.003–1.025)	0.014	1.002 (0.987–1.017)	0.792	-	-	-	-
Platelet	1.001 (1.000–1.003)	0.023	1.001 (1.000–1.003)	0.072	-	-	-	-
Risk factors for mortality								
Female	1.049 (0.832–1.324)	0.684	1.229 (0.896–1.686)	0.201	0.887 (0.737–1.068)	0.207	0.910 (0.718–1.155)	0.439
Age	1.009 (1.001–1.018)	0.028	1.016 (1.003–1.029)	0.014	1.021 (1.014–1.027)	<0.001	1.025 (1.016–1.034)	<0.001
ACLF	6.059 (4.922–7.459)	<0.001	2.716 (1.953–3.777)	<0.001	3.394 (2.844–4.052)	<0.001	1.554 (1.181–2.044)	0.002
Child-Pugh score	1.447 (1.384–1.513)	<0.001	1.278 (1.188–1.375)	<0.001	1.337 (1.290–1.386)	<0.001	1.264 (1.198–1.335)	<0.001
Bacterial infection	3.363 (2.593–4.363)	<0.001	2.256 (1.656–3.075)	<0.001	2.153 (1.798–2.579)	<0.001	1.752 (1.416–2.168)	<0.001
Hepatocellular carcinoma	2.915 (2.296–3.703)	<0.001	3.296 (2.273–4.781)	<0.001	3.698 (3.109–4.400)	<0.001	3.308 (2.542–4.306)	<0.001
Urea nitrogen	1.009 (1.008–1.011)	<0.001	1.003 (1.000–1.005)	0.027	1.008 (1.006–1.010)	<0.001	1.003 (1.000–1.005)	0.037
Leukocyte	1.022 (1.011–1.033)	<0.001	1.012 (1.000–1.025)	0.044	1.013 (1.003–1.023)	0.012	0.995 (0.979–1.010)	0.480
Portal vein thrombosis	1.466 (1.134–1.896)	0.004	1.070 (0.747–1.534)	0.711	1.584 (1.305–1.923)	<0.001	1.200 (0.932–1.546)	0.157
Sodium	0.979 (0.966–0.992)	0.002	0.999 (0.978–1.021)	0.961	0.981 (0.968–0.993)	0.003	0.988 (0.976–1.001)	0.079

ACLF, acute-on-chronic liver failure; HR, hazard ratio; sHR, subdistribution hazard ratio.

ascites, spontaneous bacterial peritonitis, bacterial infections, HE and hepatorenal syndrome, as well as significantly higher MELD and Child-Pugh scores at baseline. However, patients with ACLF had a significantly lower rate of previous bleeding, but a similar rate of primary prophylaxis compared to patients without ACLF (27.6% vs. 24.4%, $p = 0.192$).

ACLF as an independent risk factor of 42-day and 1-year rebleeding and mortality in patents with AVB

Patients with ACLF had a higher rate of rebleeding compared to patients without ACLF (42-day: 19.1% vs. 10.1%, $p < 0.001$; 1-year: 22.9% vs. 17.7%, $p = 0.024$) (Fig. 1A and B). The risk of rebleeding increased in line with ACLF grade (Fig. S2A).

Presence of ACLF, bacterial infection and non-occlusive or non-tumoral portal vein thrombosis at admission were independently associated with 42-day (multivariate ACLF: sHR 1.798; 95% CI 1.336–2.418; $p < 0.001$) and 1-year rebleeding (multivariate ACLF: sHR 1.535; 95% CI 1.183–1.992; $p = 0.001$). Hemoglobin appeared as a protective factor for the risk of rebleeding at 42 days (Fig. 1C,D, Table 2).

As expected, patients with ACLF were more prone to die than patients without ACLF (42-day: 47.1% vs. 10.0%; $p < 0.001$, 1-year: 55.0% vs. 23.1%, $p < 0.001$) (Fig. 2A,B), and mortality increased in line with severity of ACLF (Fig. S2B). These effects of ACLF on survival remained independent after adjusting for confounders (Fig. 2C,D, Table 2). Other independent risk factors associated with both 42-day and 1-year mortality were age, Child-Pugh score, bacterial infection, hepatocellular carcinoma within Milan criteria and blood urea nitrogen at baseline.

Impact of pre-emptive TIPS on rebleeding rate and mortality in patients with AVB, with or without ACLF

In the subgroup analysis of patients eligible for pTIPS, a total of 66 patients underwent pTIPS, of whom 22 (33.3%) had ACLF (Fig. S1). There were more patients with ACLF Grade III, who did not receive TIPS. While patients with ACLF receiving pTIPS had lower creatinine and glucose levels at baseline than patients with ACLF who did not receive pTIPS, there were no significant differences in age, gender, Child-Pugh score and other baseline characteristics (Table 3).

pTIPS placement was independently associated with a lower 42-day rebleeding rate (HR 0.128; 95% CI 0.017–0.937; $p = 0.043$) in patients with ACLF and treatment with pTIPS in these patients reduced the risk of rebleeding due to ACLF (Fig. 3A,B and Table S1).

Regarding mortality and in cases where the analysis was restricted to patients with ACLF, patients treated with pTIPS had a significantly lower 42-day and 1-year mortality than patients receiving standard of care (Fig. 4A). Mortality was significantly lower in the pTIPS compared to the non-pTIPS group of patients with ACLF (42-day: 13.6% vs. 51.0%, $p = 0.002$; 1-year: 22.7% vs. 56.5%, $p = 0.002$). Treatment with pTIPS reduced 42-day (multivariate sHR 0.22; 95% CI 0.07–0.74; $p = 0.014$) and 1-year (multivariate sHR 0.33; 95% CI 0.12–0.92; $p = 0.034$) mortality after adjustment for confounders (Fig. 4C,D, Table S1). Similar results were observed after adjusting for CLIF-C ACLF score instead of Child-Pugh score in the competitive Cox regression model for 42-day and 1-year mortality (Table S2). When we limited our analysis to patients with bilirubin over 5 mg/dl, pTIPS significantly increased the survival rate in patients with ACLF, regardless of hyperbilirubinemia (Fig. S3).




Fig. 2. ACLF and risk factors for mortality in patients with variceal bleeding. (A) Cumulative incidence function curve of 42-day mortality patients with or without ACLF. Levels of significance: $p < 0.0001$ (Gray's test). (B) Cumulative incidence function curve of 1-year mortality patients with or without ACLF. Levels of significance: $p < 0.0001$ (Gray's test). (C) Independent risk factors of 42-day mortality in all patients with acute variceal bleeding. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). (D) Independent risk factors of 1-year mortality in all patients with acute variceal bleeding. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). ACLF, acute-on-chronic liver failure.

In the absence of ACLF, patients treated with pTIPS also had lower mortality, but without reaching statistical significance (Table S3). Similar results can be seen in Fig. S4, showing the competing risk analysis. It is important to remark that the study was not designed to analyze this effect and it is underpowered for this analysis.

To control for the severity of liver and extrahepatic dysfunction, we performed a propensity score matched sensitivity analysis. The matched baseline characteristics of patients with ACLF, treated with and without pTIPS, are shown in Table S4. There were no significant differences between the 2 groups. In this matched cohort, pTIPS significantly improved survival in patients with ACLF, confirming the results observed in the unmatched cohort (Fig. 4E).

Discussion

This is the first study to describe the prevalence of ACLF and its relationship with rebleeding and mortality in patients with AVB. ACLF is an independent risk factor for rebleeding and mortality in patients with AVB. Moreover, patients with ACLF and AVB may benefit from placement of pTIPS.

ACLF is characterized by rapid deterioration of organ function leading to multiple organ failures and high short-term mortality.¹⁵ AVB has been described as a precipitating event for ACLF,^{15,20} but the role of ACLF on the outcomes associated with AVB has not been investigated to date. We found that a substantial percentage of patients with AVB present with ACLF. One in every 5–6 patients with AVB presented with or developed ACLF.

One of the most important and clinically relevant findings of this study was that ACLF almost doubled the risk of rebleeding, providing an easy identification criterion for patients with rebleeding risk. Interestingly, ACLF predicted this independently of the presence of portal vein thrombosis, which is a well-known risk factor for rebleeding described in several studies.^{21,22} These facts show that our cohort data collection is consistent with the literature, while confirming that our analysis is robust, despite the limitations of the study design described below.

ACLF, not surprisingly, was associated with worse prognosis in patients with AVB. However, to date, this has not been investigated thoroughly. The CANONIC study, which characterized ACLF, demonstrated that bleeding occurs similarly in

Table 3. Comparison of baseline characteristics between patients with and without pre-emptive TIPS based on baseline ACLF status.

Baseline characteristics	ACLF		p value	Non-ACLF		p value
	pTIPS (n = 22)	No pTIPS (n = 147)		pTIPS (n = 44)	No pTIPS (n = 458)	
Male, n (%)	13 (59.1)	116 (78.9)	0.058	34 (77.3)	350 (76.4)	1.000
Age	53.0 (43.8–60.5)	54.0 (49.0–60.0)	0.522	53.0 (44.3–62.0)	55.0 (47.0–62.0)	0.300
Etiology of cirrhosis, n (%)			0.754			0.262
Alcohol liver disease	16 (72.7)	94 (64.0)		31 (70.5)	260 (56.8)	
Hepatotropic virus	1 (4.5)	22 (15.0)		6 (13.6)	62 (13.5)	
Alcohol and virus	3 (13.6)	23 (15.6)		5 (11.4)	80 (17.4)	
Others	2 (9.1)	18 (5.4)		2 (4.5)	56 (12.2)	
Hepatocellular carcinoma, n (%)	0 (0.0)	4 (2.7)	1.000	1 (2.3)	4 (0.9)	0.369
Previous bleeding, n (%)	6 (27.3)	34 (23.1)	0.788	11 (25.0)	156 (34.1)	0.245
Portal vein thrombosis	0 (0.0)	8 (5.5)	0.599	2 (4.5)	27 (6.0)	1.000
Previous episode of decompensation, n (%)						
Ascites	13 (59.1)	90 (61.2)	1.000	19 (43.2)	238 (52.0)	0.274
Bacterial infection	5 (22.7)	55 (37.4)	0.235	6 (13.6)	91 (19.9)	0.424
Hepatic encephalopathy	7 (31.8)	48 (32.7)	1.000	8 (18.2)	67 (14.6)	0.509
Spontaneous bacterial peritonitis/bacteremia	2 (9.1)	24 (16.3)	0.534	3 (6.8)	24 (5.2)	0.722
Hepatorenal syndrome	1 (4.5)	6 (4.1)	1.000	1 (2.3)	8 (1.7)	0.565
Laboratory test						
Hemoglobin (g/L)	87.5 (51.0–101.3)	76.0 (63.0–90.0)	0.298	77.5 (60.0–90.3)	86.0 (68.0–101.0)	0.017
Leucocytes (10 ⁹ /L)	9.1 (6.7–12.9)	8.7 (6.1–14.1)	0.900	9.5 (6.3–12.7)	8.2 (5.8–11.6)	0.337
Platelet count (10 ⁹ /L)	76.0 (64.5–97.8)	79.0 (54.0–125.0)	0.835	89.0 (73.0–112.0)	83 (58.5–122.5)	0.296
Creatinine (mg/dl)	0.9 (0.6–1.4)	1.3 (0.8–1.8)	0.070	0.8 (0.7–1.1)	0.8 (0.6–1.0)	0.193
Urea nitrogen (mg/dl)	51.0 (24.6–91.0)	59.0 (36.0–105.0)	0.227	40.0 (18.5–51.7)	40.0 (24.8–64.0)	0.883
Na (mEq/L)	135.0 (132.9–139.8)	135.2 (131.0–140.0)	0.868	138.0 (134.1–140.8)	137.0 (134.0–140.0)	0.344
Bilirubin (mg/dl)	2.4 (1.7–5.3)	4.6 (2.1–13.0)	0.020	2.3 (1.7–4.4)	2.9 (1.7–4.5)	0.337
Albumin (g/L)	22.9 (20.6–27.9)	26.0 (22.0–29.0)	0.219	25.0 (21.3–27.2)	26.0 (22.0–29.0)	0.333
AST (U/L)	71.0 (51.0–164.0)	81.0 (48.0–143.0)	0.734	54.0 (39.0–97.0)	64.0 (41.0–112.0)	0.131
ALT (U/L)	50.0 (29.0–74.5)	39.0 (25.0–65.5)	0.386	23.0 (19.0–39.0)	34.0 (22.0–55.0)	0.025
INR	1.9 (1.6–2.4)	1.9 (1.6–2.6)	0.886	1.7 (1.5–1.8)	1.6 (1.4–1.9)	0.749
Glucose (mg/dl)	153.0 (129.0–234.5)	139.5 (103.7–171.5)	0.034	150.5 (113.5–197.8)	132.0 (109.0–173.0)	0.541
Scores						
MELD	19.0 (13.0–22.0)	22.0 (17.0–26.0)	0.021	14.0 (10.0–17.0)	13.0 (10.0–17.0)	0.620
Child-Pugh	11.0 (10.0–11.0)	11.0 (10.0–12.0)	0.362	10.0 (9.0–11.0)	10.0 (8.0–11.0)	0.755
Child B, n (%)	3 (13.6)	27 (18.4)	0.769	16 (36.4)	191 (41.7)	0.525
Child C, n (%)	19 (86.4)	120 (81.6)		28 (63.6)	267 (58.3)	
ACLF grades			0.043			
1	8 (36.4)	50 (34.0)			–	
2	13 (59.1)	56 (38.1)			–	
3	1 (4.5)	41 (27.9)			–	

ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver disease; pTIPS, pre-emptive transjugular intrahepatic portosystemic shunt. Mann-Whitney *U* test.

patients with and without ACLF. However, the present study is the first to investigate the role of ACLF in patients with variceal bleeding. Indeed, ACLF is, together with hepatocellular carcinoma, the strongest predictor of short-term mortality in variceal bleeding, with an almost 3-fold increased risk. These data are in line with the data of the CANONIC study and, again, prove the robustness of our study.¹⁵

Our results showed that ACLF is a major independent risk factor for rebleeding and mortality and that it may justify or even require more aggressive treatment. pTIPS has been introduced to treat patients at high risk of treatment failure, identified either by an hepatic venous pressure gradient over 20 mmHg, either a Child-Pugh C or Child-Pugh B with active bleeding at endoscopy.^{21,23,24} Previous studies using the latter criteria have shown that pTIPS can improve the prognosis of patients with AVB,^{10,25} without increasing the risk of complications such as HE.¹³ There are currently no related studies discussing the relationship between pTIPS and patients with ACLF. Our results suggest that pTIPS could improve the survival of patients with ACLF

remarkably. Both short-term and long-term mortality could be halved in the patients who were treated with pTIPS. Therefore, and considering the marked impact of pTIPS on rebleeding and most importantly on short-term mortality, this therapeutic tool should be considered in the management of patients with ACLF and AVB, even in patients with bilirubin higher than 5 mg/dl. The consequence of this hypothesis would be to transfer the affected patients to hospitals with access to TIPS, thereby potentially reducing their mortality rate by 75%. These data are nicely supported by a recent study which showed that the higher the MELD score, the bigger the survival benefit after pTIPS.²⁵ Despite a reduction in mortality observed in patients without ACLF, the statistical significance was not achieved. This is because mortality in these patients is much lower and therefore the sample size needed to demonstrate a potential significant benefit is higher than the 44 patients evaluated. Further studies must dissect the role of pTIPS in high-risk patients without ACLF.

These results could be confirmed after controlling for confounders using propensity score matching. However, this study




Fig. 3. Pre-emptive TIPS and risk factors for rebleeding in patients with ACLF and acute variceal bleeding. (A) Cumulative incidence function curve of 42-day rebleeding rate in patients with ACLF, with or without pre-emptive TIPS. Levels of significance: $p = 0.0285$ (Gray's test). (B) Risk factors for 42-day rebleeding in patients with ACLF, with or without pre-emptive TIPS. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). ACLF, acute-on-chronic liver failure; TIPS, transjugular intrahepatic portosystemic shunt.

had several limitations. While the data collection process of this study is prospective, multi-centered and large-scale, it lacked the on-site monitoring visit of a randomized control trial. Moreover, ACLF was diagnosed retrospectively, since the study had been planned before publication of the EASL-ACLF criteria. The precise information on vasoactive drug use were retrieved from the CRFs, and those patients treated with vasoactive drugs to maintain blood pressure were defined as having circulatory failure. Additionally, in the database, the need for mechanical ventilation without HE grade III or IV at admission was reported as respiratory failure. However, the result was confirmed by propensity score matching and thus had a high degree of consistency. Additionally, data regarding ACLF development after variceal bleeding were not collected. Unfortunately, we cannot clarify whether bleeding was the precipitating event of ACLF. Still, we believe that the study is relevant in real clinical practice. Another limitation of this study is the limited number of patients with ACLF treated with pTIPS, even though this is the largest and first study investigating pTIPS in this population. Further studies assessing the role of pTIPS on outcomes in patients with ACLF are needed to validate these results.

This large, multicenter, international study confirms that ACLF is frequent in patients with AVB, that ACLF is an independent predictor of rebleeding and mortality, and that pTIPS could improve survival in patients with ACLF and AVB.

Abbreviations

ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVB, acute variceal bleeding; HE, hepatic encephalopathy; HR, hazard ratio; ICU, intensive care unit; INR, international normalized ratio; MELD, model for end-stage liver disease; sHR, subdistribution HR; pTIPS, pre-emptive TIPS; TIPS, transjugular intrahepatic portosystemic shunt.

Financial support

CIBERehd is funded by Instituto de Salud Carlos III. Juan Carlos Garcia - Pagan is supported by Ministerio de Educación y Ciencia (SAF - 2016 - 75767 - R). Virginia Hernández - Gea is supported by Instituto de Salud Carlos III (PI14/00182). Gilberto Silva - Junior is funded by CAPES Foundation, Ministry of Education of Brazil, Brasília, Brazil (process number BEX 5960/13 - 4). Edilmar Alvarado is supported by a Rio Hortega Fellowship grant from Instituto de Salud Carlos III. Jonel Trebicka is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), European Union's Horizon 2020 Research and Innovation Programme (Galaxy, No. 668031 and MICROB-PREDICT, No. 825694) and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875), and Cellex Foundation (PREDICT). Gu W is supported by the China Scholarships Council (CSC: #201906230332). Rafael Bañares is funded by Instituto de Salud Carlos III (PI18/01901). Michael Praktiknjo is funded by the Ernst und Berta Grimmke Stiftung (Lfd.Nr. 5/19).

The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript.

Conflict of interest

Christophe Bureau has received speaker fees from GORE and is a board member of Alfawassenran/Norgine. Virginia Hernández - Gea, Álvaro Giráldez, Jaume Bosch, Agustin Albillos, Dominique Thabut, Michael Praktiknjo and Frederik Nevens have received speaker fees from GORE. Juan Carlos Garcia - Pagan has received consultant fees from GORE, Shionogi and Cook grants from GORE and Novartis. Jonel Trebicka has received speaking and/or consulting fees from GORE, Bayer, Alexion, MSD, Gilead, Intercept, Norgine, Grifols, Versantis, and Martin Pharmaceutical, and




Fig. 4. Pre-emptive TIPS and risk factors for mortality in patients with ACLF and acute variceal bleeding. (A) Cumulative incidence function curve of 42-day mortality rate in patients with ACLF, with or without pre-emptive TIPS. Levels of significance: $p = 0.0016$ (Gray's test). (B) Cumulative incidence function curve of 1-year mortality rate in patients with ACLF, with or without pre-emptive TIPS. Levels of significance: $p = 0.0023$ (Gray's test). (C) Risk factors for 42-day mortality in patients with ACLF, with or without pre-emptive TIPS. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). (D) Risk factors for 1-year mortality in patients with ACLF, with or without pre-emptive TIPS. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). (E) Cumulative incidence function curve of 42-day mortality rate in patients with ACLF, with or without pre-emptive TIPS after propensity score matching. Levels of significance: $p = 0.0067$ (Gray's test). ACLF, acute-on-chronic liver failure; TIPS, transjugular intrahepatic portosystemic shunt.

Rafael Bañares has received speaker fees from GORE and Grifols, unrelated to the submitted work.

Please refer to the accompanying [ICMJE disclosure](#) forms for further details.

Authors' contributions

JT and RB: study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content,

statistical analysis, obtained funding, technical or material support and study supervision. WG and CJ: acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, statistical analysis, obtained funding and technical or material support. VHJ, JG, JB and JCGP: acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, statistical analysis, obtained funding, technical or material support and study supervision. CP, EG, FT and MP: analysis and interpretation of data. LI, BP, AG, LA, CV, DT, GSJ, JM, CB, EL, WL, JMP, JC, SR, LLG, CFN, RB, NC, MR, AF, JLM, HG, MHG, RS, ADE, MS, JGA, MRG, AZ, MC, HM, MP, EW, MVC, HPE, FEU, MS, MB, MP, JC, AK, FN, JLC, MAR, IC, AA, MR, EA, MAG and MT: acquisition of data and critical revision of the manuscript for important intellectual content.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2020.04.024>.

References

Author names in bold designate shared co-first authorship

- [1] Bosch J, Abraldes JG, Albillos A, Aracil C, Banares R, Berzigotti A, et al. Portal hypertension: recommendations for evaluation and treatment: consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for liver and digestive Diseases (CIBERehd). *Gastroenterol Hepatol* 2012;35:421–450.
- [2] Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. *Gastroenterology* 2014;146:412–419.e3.
- [3] Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. *Liver Int* 2017;37(Suppl 1):104–115.
- [4] O'Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. *Nat Rev Gastroenterol Hepatol* 2013;10:402–412.
- [5] Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. *N Engl J Med* 2010;362:2370–2379.
- [6] Cabrera L, Tandon P, Abraldes JG. An update on the management of acute esophageal variceal bleeding. *Gastroenterol Hepatol* 2017;40:34–40.
- [7] Conejo I, Guardascione MA, Tandon P, Cachero A, Castellote J, Abraldes JG, et al. Multicenter external validation of risk stratification criteria for patients with variceal bleeding. *Clin Gastroenterol Hepatol* 2018;16:132–139.e8.
- [8] de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015;63:743–752.
- [9] Njei B, McCarty TR, Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. *J Gastroenterol Hepatol* 2017;32:852–858.
- [10] Thabut D, Pauwels A, Carbonell N, Remy AJ, Nahon P, Causse X, et al. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. *J Hepatol* 2017;68:73–81.
- [11] Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, et al. Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. *Dig Liver Dis* 2017;49:1360–1367.
- [12] Deltenre P, Trepo E, Rudler M, Monescillo A, Fraga M, Denys A, et al. Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: a systematic review and meta-analysis of controlled trials. *Eur J Gastroenterol Hepatol* 2015;27:e1–e9.
- [13] Hernandez-Gea V, Procopet B, Giraldez A, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. *Hepatology* 2019;69:282–293.
- [14] Lee YY, Tee HP, Mahadeva S. Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. *World J Gastroenterol* 2014;20:1790–1796.
- [15] Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013;144:1426–1437. 1437.e1–9.
- [16] Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. *J Hepatol* 2012;57:1336–1348.
- [17] Garg H, Kumar A, Garg V, Kumar M, Kumar R, Sharma BC, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. *J Gastroenterol Hepatol* 2013;28:1361–1367.
- [18] Trebicka J. Emergency TIPS in a Child-Pugh B patient: when does the window of opportunity open and close? *J Hepatol* 2017;66:442–450.
- [19] de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatol* 2010;53:762–768.
- [20] Bernal W, Jalan R, Quaglia A, Simpson K, Wendon J, Burroughs A. Acute-on-chronic liver failure. *Lancet* 2015;386:1576–1587.
- [21] D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. *Hepatology* 2003;38:599–612.
- [22] Qi X, He C, Guo W, Yin Z, Wang J, Wang Z, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. *Liver Int* 2016;36:667–676.
- [23] **Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al.** Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. *J Hepatol* 2013;58:45–50.
- [24] Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jimenez E, et al. Influence of portal hypertension and its early decompensation by TIPS placement on the outcome of variceal bleeding. *Hepatology* 2004;40:793–801.
- [25] **Lv Y, Zuo L, Zhu X, Zhao J, Xue H, Jiang Z, et al.** Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study. *Gut* 2019;68:1297–1310.